ArticleObesity surgery2026
Outcomes of Metabolic and Bariatric Surgery in Adolescents and Young Adults versus Adults: A Comparative Cohort Study.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic and bariatric surgery (MBS) is an effective treatment for severe obesity, but comparative data between adolescents and young adults (AYA) and adults remain limited. This study aimed to evaluate weight loss and metabolic outcomes after MBS in AYA compared with adults.
methodsWe conducted a retrospective cohort study including AYA (≤ 21 years) and adults (> 21 years) who underwent MBS (sleeve gastrectomy and Roux-en-Y gastric bypass) between 2013 and 2023. Propensity score matching was performed separately for each outcome at each follow-up time point, using nearest-neighbor matching (up to three adult controls per AYA, without replacement) based on baseline characteristics (type of surgery, sex, BMI, prediabetes, hypertension, and dyslipidemia). Weight loss and metabolic outcomes (prediabetes, hypertension, dyslipidemia) were assessed at 1-, 2-, and 3-year follow-up.
resultsAt 1 year, AYA achieved lower percentage of total weight loss (%TWL) compared with adults (21.2% vs. 32.5%; average treatment effect on the treated (ATT) - 11.2%; 95% CI - 14.2 to - 8.3; p < 0.001). Similar differences were observed at 2 years (25.9% vs. 31.7%; ATT - 5.8%; 95% CI - 9.9 to - 1.7; p = 0.006), and 3 years (29.8% vs. 31.5%; ATT - 1.7%; 95% CI - 5.2 to 1.7; p = 0.324). Prevalence of dyslipidemia was lower in AYA at 3 years (18.9% vs. 35.1%; ATT - 16.2%; 95% CI - 32.1 to - 0.4; p = 0.045).
conclusionsMBS was effective in both groups, leading to significant weight loss and metabolic improvements. Despite lower early weight loss, AYA achieved metabolic outcomes comparable to adults. A lower prevalence of dyslipidemia was observed among AYA at later follow-up in the primary analysis, although this finding was not robust to exclusion of participants receiving statins at baseline. Larger studies with standardized follow-up and longer-term observation are warranted to confirm these findings.
Indexed as
Identifiers
42789201What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.